Kimberly Ho
Physician Assistant · Los Angeles, CANPI 1053801670
Payments from drug & device makers
Across 681 payments — averaging $24.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Bristol Myers Squibb$1K
- Merck$998
- Astellas Pharma US Inc$950
- Pfizer$882
- Incyte Corporation$801
- plus $9K from 53 others
What the payments were for
- Food & beverage$14,34086%
- Education$1,1657%
- Other$1,2327%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,737 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 49 | $661,194 |
| RevlimidLenalidomide | 32 | $567,258 |
| ImbruvicaIbrutinib | 29 | $450,171 |
| TagrissoOsimertinib Mesylate | 24 | $407,734 |
| CalquenceAcalabrutinib Maleate | 24 | $357,398 |
| BrukinsaZanubrutinib | 14 | $196,466 |
| Lenalidomide | 13 | $188,409 |
| ErleadaApalutamide | 12 | $173,082 |
| JakafiRuxolitinib Phosphate | 14 | $170,796 |
| PromactaEltrombopag Olamine | 18 | $159,023 |
| OrgovyxRelugolix | 40 | $106,218 |
| Lupron DepotLeuprolide Acetate | 11 | $67,040 |
| EliquisApixaban | 42 | $26,202 |
| ProcritEpoetin Alfa | 13 | $25,304 |
| XareltoRivaroxaban | 20 | $10,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $438 | $765,13148 claims |
| Astellas Pharma US IncXtandi | $950 | $661,19449 claims |
| Bristol Myers SquibbRevlimid | $1,184 | $567,25832 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $138 | $450,17129 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $572 | $208,99945 claims |
| Beigene USA, Inc.Brukinsa | $182 | $196,46614 claims |
| Incyte CorporationJakafi | $801 | $170,79614 claims |
| NovartisPromacta | $2,534 | $159,02318 claims |
| AbbVieLupron Depot | $310 | $67,04011 claims |
| PfizerEliquis | $882 | $26,20242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Los Angeles
- Eric CheungLos Angeles$213K
- Asia SullivanLos Angeles$61K
- Felipe FindleyLos Angeles$51K
- Melissa GriffinLos Angeles$39K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.